| Biomarker ID | 1439 |
| PMID | 24893170 |
| Year | 2014 |
| Biomarker | miR_19a + miR_19b + miR_345 + miR_519c_5p |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: [miR_19a: 0.89 (95% CI: 0.01, 55.72)]; [miR_19b: 17.38 (95% CI: 0.21-1431.62 )]; [miR_345: 0.002 (95% CI: 0.00-0.42)]; [miR_519c_5p: 0.16 (95% CI: 0.01-3.14)]; |
| Effect on Pathways | NA |
| Experiment | Gleason Score ≥7 or Gleason Score =6 |
| Type of Biomarker | Prognostic |
| Cohort | A validation cohort consisted of 25 cases and 35 controls. Gleason score of 7 or higher (case group) and a pathologic Gleason score of 6 (control group). |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.940 (95% CI: 0.87-1.00) |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |